Further re. Conditional Sale of Pharm2Farm holding

RNS Number : 5035C

Braveheart Investment Group plc

19 October 2020

 

19 October 2020

Braveheart Investment Group plc

("Braveheart" or the "Group")

Further re. Conditional Sale of Pharm 2 Farm Limited holding

On 21 August 2020, Braveheart announced the conditional sale its 51.72% holding in Pharm 2 Farm Limited ("P2F") to Remote Monitored Systems plc ("RMS") for a consideration of 310,354,815 new Ordinary Shares of 0.2p each in RMS ("RMS Shares") ("Consideration Shares") ("P2F Sale") .

The P2F sale is conditional, among other things, on the Takeover Panel granting a waiver of the Rule 9 obligations arising out of the P2F Sale and the independent shareholders of RMS approving the whitewash of Braveheart's Rule 9 obligations at a general meeting.

RMS announced earlier today that a shareholder circular (the "   RMS   Circular   ") will be published today that contains information relating to the P2F Sale and includes a notice convening a general meeting of RMS (the "   RMS   General Meeting   "). The RMS General Meeting will be held at 10:30 a.m. on 4 November 2020 . The RMS Circular is expected to be posted to RMS Shareholders shortly.

The P2F Sale is expected to be completed on 5 November 2020, subject to, amongst other things, the passing of the resolutions, including the resolution seeking approval of the whitewash of Braveheart's Rule 9 obligations by the   independent shareholders of RMS, at the RMS General Meeting.

A further announcement will be made in due course.

For further information:

Braveheart Investment Group plc Tel: [phone] Trevor Brown CEO Allenby Capital Limited (Nominated Adviser and Joint Broker) Tel: [phone] David Worlidge / James Hornigold Peterhouse Capital Limited (Joint Broker) Tel: [phone] Heena Karani / Lucy Williams

 

END

 

 

FURMLBBTMTJBBPM